Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338650 · ClinicalTrials.gov registry record · Phase 3
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT00338650 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 1,000 participants.
The verdict
NCT00338650, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety
Interventions
- DRUG adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338650
The ClinicalTrials.gov registry entry for NCT00338650 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which adalimumab is the first listed.
NCT00338650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338650 about?
NCT00338650 is a clinical study titled "Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)". The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety
What is the current status of trial NCT00338650?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00338650?
The interventions under investigation include: adalimumab (DRUG).
Who is sponsoring clinical trial NCT00338650?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.